865156-59-8

Basic information

• Product Name: 4-broMo-6-Methylpyridin-2-ol
• Synonyms: 4-BroMo-6-Methyl-2(1H)-pyridinone
• CAS NO: 865156-59-8
• Molecular Formula: C₆H₆BrNO
• Molecular Weight: 188.02194
• Mol File: 865156-59-8.mol

Chemical Properties

• Boiling Point: 295.1±40.0 °C(Predicted)
• Appearance: /
• Density: 1.622±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 10?+-.0.10(Predicted)
• CAS DataBase Reference: 4-broMo-6-Methylpyridin-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-broMo-6-Methylpyridin-2-ol(865156-59-8)
• EPA Substance Registry System: 4-broMo-6-Methylpyridin-2-ol(865156-59-8)

Safety Data

• Hazardous Substances Data: 865156-59-8(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
4-Bromo-6-methylpyridin-2-ol is used as an intermediate in the synthesis of organic compounds. Its presence of a bromine atom and a methyl group allows for further chemical reactions, making it a valuable component in the creation of new materials and products.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 4-bromo-6-methylpyridin-2-ol is utilized in the production of pharmaceutical drugs. Its unique structure and properties contribute to the development of new medications, potentially enhancing the efficacy and scope of available treatments.
Used in Medicinal Chemistry:
Due to its potential biological activities, 4-bromo-6-methylpyridin-2-ol may have applications in the field of medicinal chemistry. Researchers can explore its interactions with biological systems to discover new therapeutic agents or improve existing ones.
Overall, 4-bromo-6-methylpyridin-2-ol is a multifaceted chemical with a broad spectrum of uses across different sectors, highlighting its importance in modern scientific and industrial applications.

Upstream product

• 3749-51-7 4-hydroxy-6-methyl-2-pyridone 
• 3749-51-7 2,4-dihydroxy-6-methylpyridine 

Downstream Products

• 1083169-00-9 4-bromo-2-methoxy-6-methylpyridine 

Relevant articles and documents

Preparation method of 4-bromo-6-chloropyridine-2-carboxylic acid

The invention relates to a preparation method of 4-bromo-6-chloropyridine-2-carboxylic acid. The preparation method of the 4-bromo-6-chloropyridine-2-carboxylic acid comprises the following steps: carrying out primary substitution reaction on 2,4-dihydroxy-6-methylpyridine and one of phosphorus oxybromide, phosphorus pentabromide or tetrabutylammonium bromide to generate 2-hydroxy-4-bromo-6-methylpyridine; carrying out secondary substitution reaction on the 2-hydroxy-4-bromine-6-methyl pyridine and phosphorus oxychloride or phosphorus pentachloride to generate 4-bromine-6-methyl-2-pyridine; according to the preparation method of the 4bromo 6chloropyridine 2carboxylic acid, the raw materials are cheap and easy to obtain, column chromatography purification is not needed in the reaction process, and the operation is simple and convenient.

Pyridine N-oxidation derivative as well as preparation method and application thereof

The invention relates to a pyridine N-oxidation derivative as well as a preparation method and an application thereof, in particular to a compound shown in a general formula (I), a preparation methodof the compound, pharmaceutical composition containing the compound and an application of the compound as a BRD4 inhibitor in treating related diseases such as cancer, inflammation, chronic liver diseases, diabetes, cardiovascular diseases, AIDS and the like, wherein in the general formula (I), all substituent groups are the same as definitions in the description.

METHODS OF USING SUBSTITUTED PYRAZOLE AND PYRAZOLE COMPOUNDS AND FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES

Disclosed are methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formula (I), in which X1, X2, Z1, Z2, the ring system denoted by "a", R1, L1, L2, Q, L3, R3, L4, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene.

SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO

Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts and /V-oxides thereof, wherein X1, X2, Z1, Z2, the ring system denoted by "a", R1, A1A, L1B, A1B, L1A, L2, Q, L3, R3, A4A, L4B, A4B, L4A, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein disrupt the elF4E/eiF4G interaction, and can be used to treat hyperproliferative disorder, a neurological disease or disorder, or autism.

IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula ( I ) represented by the following:The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.

5-AMINO-4-HYDROXY-7-(1H-INDOLMETHYL)-8-METHYLNONAMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION

The application relatés to novel alkanamides of the general formula (I) where X is -CH2- or >CH-OH; (A) R1 is e.g. an optionally substituted heterocyclyl radical or an optionally substituted polycyclic, unsaturated hydrocarbon radical where X is hydroxymethylene; R2 is C1-C6-alkyl or C3-C6-cydoalkyl; R3 are each independently H, C1-C6-alkyl, C1-6-alkoxycarbonyl or C1-C6-alkanoyl; R4 is C1-C6-alkyl, C3-C6-cycloalkyl, C2-C6-alkenyl or unsubstituted or substituted aryl-C1-C6-alkyl; R5 is Cl-C6-alkyl, C1-C6-hydroxyalkyl, C1-C6-alkoxy-C1-C6-alkyl, C1-C6-alkanoyloxy- C1-C6-alkyl, C1-C6-aminoalkyl, C1-C6-alkylamino-C1-C6-alkyl, C1-C6-dialkylamino-Cl-C6-alkyl, C1-C6-alkanoylamido-C1-C6-alkyl, HO(O)C-C1-C6-alkyl, C1-C6-alkyl-O-(O)C-C1-C6-alkyl, H2N-C(O)-C1-C6-alkyl, C1-C6-alkyl-HN-C(O)-C1-C6-alkyl, (C1,-C6-alkyl)2N-C(O)-C1-C6-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, cyano-C1-C6-alkyl, halo-Cl-C6-alkyl, optionally substituted aryl--Co-C6-alkyl, optionally substituted C3-C8-cycloalkyl-Co-C6-alkyl or optionally substituted heterocydyl-Co-C6-alkyl; to a process for their preparation and to the use of these compounds as medicines, especially as renin inhibitors for the treatment of hypertension.

ORGANIC COMPOUNDS

The invention relates to novel amino alcohols of the general formula (I) where X, R1, R2, R3, R4, R5 and R6 are each as defined in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors.